Diabetes Care 35 , 12251231 (2012)
Author contributions All authors contributed to conception and design, analysis and interpretation of the evidence, drafting of the manuscript, finalization of the manuscript, and the decision to submit to publication
The results demonstrated that the 25mg daily pill delivered clinically meaningful weight loss: Average weight loss of 13.6-16.6% compared to 2.2-2.7% with placebo 76% of participants achieved at least 5% weight loss versus 31% on placebo Over 30% achieved 20% or greater weight loss Significant improvements in blood pressure, cholesterol, and inflammatory markers These results are comparable to what weve seen with injectable Wegovy, which typically produces 12-15% weight loss
Vyvanse is available only as a brand-name medication
Directly activating GIPR in hepatocytes is an unlikely explanation for the decrease in apoC-III levels with tirzepatide [91, 92]
We excluded individuals prescribed with GLP-1 RAs or SGLT-2 inhibitors before index date in the GLP-1 RA vs
